L G Dressler

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. ncbi request reprint Handling, storage, and preparation of human tissues
    L G Dressler
    University of North Carolina, Chapel Hill, North Carolina, USA
    Curr Protoc Cytom . 2001
  2. ncbi request reprint Genetic testing for the BRCA1 gene and the need for protection from discrimination: an evolving legislative and social issue
    L Dressler
    Department of Medicine, University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7295, USA
    Breast Dis 10:127-35. 1998
  3. ncbi request reprint HER2 testing: laboratory, technical and clinical considerations
    L G Dressler
    University of North Carolina, Lineberger Comprehensive Cancer Center, Department of Medicine, Chapel Hill, North Carolina 27599 7295, USA
    Breast Dis 11:77-87. 2000
  4. ncbi request reprint Policy guidelines for the utilization of formalin-fixed, paraffin-embedded tissue sections: the UNC SPORE experience. University of North Carolina Specialized Program of Research Excellence
    L G Dressler
    The University of North Carolina, Lineberger Comprehensive Cancer Center and School of Public Health, Department of Medicine, Chapel Hill 27599 7295, USA
    Breast Cancer Res Treat 58:31-9. 1999
  5. ncbi request reprint Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients
    Lynn G Dressler
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB 7295, Mason Farm Rd, Chapel Hill, NC 27599 7295, USA
    J Clin Oncol 23:4287-97. 2005
  6. doi request reprint How will GINA influence participation in pharmacogenomics research and clinical testing?
    L G Dressler
    Division of Pharmaceutical Outcomes and Policy, Institute of Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA
    Clin Pharmacol Ther 86:472-5. 2009
  7. pmc Epidemiology of basal-like breast cancer
    Robert C Millikan
    Department of Epidemiology, CB 7435, School of Public Health, University of North Carolina, Chapel Hill, NC 27599 7435, USA
    Breast Cancer Res Treat 109:123-39. 2008
  8. ncbi request reprint HER2 and response to paclitaxel in node-positive breast cancer
    Daniel F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA
    N Engl J Med 357:1496-506. 2007
  9. doi request reprint Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B
    Michael P Digiovanna
    Yale University School of Medicine, Section of Medical Oncology, 333 Cedar St, Room WWW 217, New Haven, CT 06510, USA
    J Clin Oncol 26:2364-72. 2008
  10. ncbi request reprint Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
    Lisa A Carey
    Division of Hematology Oncology, School of Public Health, Department of Epidemiology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    JAMA 295:2492-502. 2006

Research Grants

  1. TUMOR MARKERS TO PREDICT TREATMENT RESPONSE
    Lynn Dressler; Fiscal Year: 2005
  2. Disclosure of Results from Genetic Research Studies
    Lynn Dressler; Fiscal Year: 2006

Collaborators

Detail Information

Publications12

  1. ncbi request reprint Handling, storage, and preparation of human tissues
    L G Dressler
    University of North Carolina, Chapel Hill, North Carolina, USA
    Curr Protoc Cytom . 2001
    ..Other protocols detail preparation of intact nuclei from fresh, frozen, or paraffin-embedded tissue. Support protocols cover fixation, cryospin preparation, cryopreservation, and removal of debris...
  2. ncbi request reprint Genetic testing for the BRCA1 gene and the need for protection from discrimination: an evolving legislative and social issue
    L Dressler
    Department of Medicine, University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7295, USA
    Breast Dis 10:127-35. 1998
    ..Although progress has been made, troublesome issues still remain...
  3. ncbi request reprint HER2 testing: laboratory, technical and clinical considerations
    L G Dressler
    University of North Carolina, Lineberger Comprehensive Cancer Center, Department of Medicine, Chapel Hill, North Carolina 27599 7295, USA
    Breast Dis 11:77-87. 2000
    ..In addition, there is need to set standards for assay performance and interpretation of assay results, based on criteria that are clinically validated...
  4. ncbi request reprint Policy guidelines for the utilization of formalin-fixed, paraffin-embedded tissue sections: the UNC SPORE experience. University of North Carolina Specialized Program of Research Excellence
    L G Dressler
    The University of North Carolina, Lineberger Comprehensive Cancer Center and School of Public Health, Department of Medicine, Chapel Hill 27599 7295, USA
    Breast Cancer Res Treat 58:31-9. 1999
    ..It is our hope that the information and experience described here may stimulate discussion that can ultimately lead to a uniform policy for handling formalin-fixed paraffin-embedded tissues in research...
  5. ncbi request reprint Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients
    Lynn G Dressler
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB 7295, Mason Farm Rd, Chapel Hill, NC 27599 7295, USA
    J Clin Oncol 23:4287-97. 2005
    ....
  6. doi request reprint How will GINA influence participation in pharmacogenomics research and clinical testing?
    L G Dressler
    Division of Pharmaceutical Outcomes and Policy, Institute of Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA
    Clin Pharmacol Ther 86:472-5. 2009
    ..How will GINA, which takes effect in 2009, influence participation in pharmacogenomic research and clinical testing?..
  7. pmc Epidemiology of basal-like breast cancer
    Robert C Millikan
    Department of Epidemiology, CB 7435, School of Public Health, University of North Carolina, Chapel Hill, NC 27599 7435, USA
    Breast Cancer Res Treat 109:123-39. 2008
    ..Among younger African-American women, we estimate that up to 68% of basal-like breast cancer could be prevented by promoting breastfeeding and reducing abdominal adiposity...
  8. ncbi request reprint HER2 and response to paclitaxel in node-positive breast cancer
    Daniel F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA
    N Engl J Med 357:1496-506. 2007
    ..We hypothesized that HER2 positivity predicts a benefit from adjuvant doxorubicin doses above standard levels, from the addition of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide, or from both...
  9. doi request reprint Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B
    Michael P Digiovanna
    Yale University School of Medicine, Section of Medical Oncology, 333 Cedar St, Room WWW 217, New Haven, CT 06510, USA
    J Clin Oncol 26:2364-72. 2008
    ....
  10. ncbi request reprint Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
    Lisa A Carey
    Division of Hematology Oncology, School of Public Health, Department of Epidemiology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    JAMA 295:2492-502. 2006
    ..Gene expression analysis has identified several breast cancer subtypes, including basal-like, human epidermal growth factor receptor-2 positive/estrogen receptor negative (HER2+/ER-), luminal A, and luminal B...
  11. ncbi request reprint Mutation of GATA3 in human breast tumors
    Jerry Usary
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Oncogene 23:7669-78. 2004
    ..These data suggest that GATA3 is involved in growth control and the maintenance of the differentiated state in epithelial cells, and that GATA3 variants may contribute to tumorigenesis in ESR1-positive breast tumors...
  12. ncbi request reprint Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbuilt Ingram Cancer Center, Vanderbuilt University School of Medicine, Nashville, Tennessee 37232, USA
    Cancer Cell 5:489-500. 2004
    ..This work represents an important step toward the identification of clinically significant biomarkers for HNSCC...

Research Grants2

  1. TUMOR MARKERS TO PREDICT TREATMENT RESPONSE
    Lynn Dressler; Fiscal Year: 2005
    ..Two subcontracts are included in this proposal, one to support the CALGB Pathology Coordinating Office functions at OSU relevant to this study and the other in support of the molecular studies being performed by USC. ..
  2. Disclosure of Results from Genetic Research Studies
    Lynn Dressler; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..